Loading...
Market
What will be the outcome of legal challenges to Trump's border closure justification by December 31, 2025?
2
Resolution / Starting Odds
Upheld • 25%
Struck down • 25%
Partially upheld • 25%
Other • 25%
Court rulings or legal documents
Story
Trump Advisers Explore Diseases for Border Closure Justification, Including Tuberculosis and Title 42 Strategy After Months of Research
Jan 9, 2025, 10:30 PM
Advisers to President-elect Donald Trump are reportedly exploring various diseases to justify the closure of the U.S.-Mexico border. According to multiple sources, they have been searching for the right disease for several months. Specific diseases under consideration include tuberculosis and other respiratory illnesses. The advisers have also reached out to Border Patrol allies for examples of illnesses currently detected among migrants. This initiative appears to be a strategic move to leverage health concerns in support of border closure policies, reminiscent of the use of Title 42 during the COVID-19 pandemic.
View original story
Similar markets
Policies partially struck down • 25%
Policies completely struck down • 25%
No legal challenges • 25%
Policies upheld • 25%
Settled • 25%
Pending • 25%
Struck Down • 25%
Upheld • 25%
No significant legal challenges • 25%
Proposals upheld in court • 25%
Proposals partially upheld • 25%
Proposals struck down • 25%
Policy upheld • 25%
Policy struck down • 25%
Policy modified • 25%
Pending resolution • 25%
No significant challenges • 25%
Some challenges, some successful • 25%
Some challenges, none successful • 25%
Majority of challenges successful • 25%
Plan upheld • 25%
Plan modified • 25%
Ongoing litigation • 25%
Plan blocked • 25%
Challenges in lower courts only • 25%
Challenges reaching the Supreme Court • 25%
No significant legal challenges • 25%
Challenges reaching appellate courts • 25%
Upheld by courts • 25%
No decision by end of 2025 • 25%
Partially upheld • 25%
Struck down by courts • 25%
No Major Challenges • 25%
Majority Upheld • 25%
Majority Overturned • 25%
Mixed Outcomes • 25%